Previous close | 16.09 |
Open | 16.61 |
Bid | 16.72 x 100 |
Ask | 16.82 x 100 |
Day's range | 16.48 - 16.98 |
52-week range | 14.38 - 24.90 |
Volume | |
Avg. volume | 95,637 |
Market cap | 2.252B |
Beta (5Y monthly) | 0.11 |
PE ratio (TTM) | 419.75 |
EPS (TTM) | 0.04 |
Earnings date | 25 Jul 2024 - 29 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 16 Jun 2016 |
1y target est | 36.00 |
Indivior PLC (LSE/Nasdaq: INDV) today announced the publication of a modeling study in Frontiers in Psychiatry that predicts OPVEE (nalmefene) nasal spray (2.7 mg nalmefene, equivalent to 3 mg of nalmefene hydrochloride) resulted in larger reductions in the incidence of simulated cardiac arrest following overdose from high doses of potent synthetic opioids, compared to a 4 mg dose of IN naloxone.
Indivior PLC (LSE/Nasdaq: INDV) today announced the dosing of the first subject with INDV-2000 in a Phase 2 double-blind, placebo controlled, randomized, dose-ranging study to assess the safety and efficacy of INDV-2000 over 3 months in treatment-seeking individuals with Opioid Use Disorder (OUD) (NCT06384157). The purpose of this proof-of-concept study is to measure safety and efficacy and to determine the dose-response relationship for INDV-2000 in participants with moderate to severe OUD who
Key Insights Institutions' substantial holdings in Indivior implies that they have significant influence over the...